Curated News
By: NewsRamp Editorial Staff
June 22, 2026
Sandoz Capital Markets Day: Biosimilars’ Golden Decade
TLDR
- Sandoz's capital markets day on Sept 8 offers investors strategic insights to capitalize on its golden decade for biosimilars.
- Sandoz hosts a capital markets day and Slovenia site visit to detail its biosimilars development and supply-chain hub.
- Sandoz's affordable medicines reach over one billion patients, generating substantial global healthcare savings and social impact.
- Sandoz celebrates 140 years of heritage in 2026, marking 20 years of pioneering biosimilars and 80 years of antibiotics.
Impact - Why it Matters
This news matters because Sandoz is a bellwether for the global generics and biosimilars industry, which directly affects healthcare costs and patient access to life-saving medications. The capital markets day will outline strategies that could lower drug prices, expand treatment options, and drive competition in the biosimilars market, potentially saving billions in healthcare spending. For investors, it offers a glimpse into Sandoz’s growth trajectory and financial outlook, impacting portfolio decisions. For patients, successful execution could mean more affordable biologics for chronic and complex diseases.
Summary
Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, announced it will host its 2026 capital markets day on Tuesday, 8 September, from 13:30-17:00 UK time at the London Stock Exchange. The event will be held in-person and via live webcast, with in-person attendance by invitation only on a first-come, first-served basis. Details on accessing the live webcast are available here. Additionally, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November, offering deeper insight into its new biosimilars development and supply-chain hub. This visit is also invitation-only and will not be webcasted.
Sandoz, headquartered in Basel, Switzerland, is celebrating a milestone year in 2026: 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing, and 140 years of heritage. With a portfolio of approximately 1,300 medicines addressing conditions from the common cold to cancer, Sandoz reached over one billion patients in 2025, generating net sales of USD 11.1 billion. The capital markets day is expected to showcase the company's strategy to maximize value in what it calls its 'golden decade for biosimilars,' as highlighted in the original release on www.newmediawire.com.
The event will feature presentations from Sandoz leadership, focusing on growth drivers, pipeline updates, and financial targets. Investors and analysts will gain insights into how Sandoz plans to leverage its leadership in biosimilars and generics to drive affordable access to medicines globally. The Slovenia site visit will further highlight the company's advanced biosimilars capabilities, reinforcing its commitment to innovation and supply chain resilience. Sandoz's forward-looking statements caution that actual results may vary due to risks such as market conditions and regulatory changes.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sandoz Capital Markets Day: Biosimilars’ Golden Decade
